2013-09-05T12:05:13-05:00 2012-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2012-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Michael W Marine 2028428610 2013-08-30 1 Nicole M Simon CPA P01315245 7038930300 2013-08-27 2012 2016-02-24 21:20:13Z Michael W Marine 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 25361273 0 X www.sabin.org X 1994 MD An organization of scientists, researchers and advocates for a world free of needless suffering. 10 9 70 0 0 0 22266964 25314757 0 0 24717 30674 0 842 22291681 25346273 11186989 7832968 0 0 4720439 5037610 122195 52974 317938 8672834 8510014 24702457 21433566 -2410776 3912707 25035530 27301935 4617860 2971558 20417670 24330377 X To reduce needless human suffering from vaccine-preventable and neglected tropical diseases through innovative vaccine research and development; and to advocate for improved access to vaccines and essential medicines for citizens around the globe. 0 0 6925598 4235392 Sabin Vaccine Insitute Product Development Partnership (Sabin PDP)With 13 years of research and development experience, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has produced a well-rounded, low-cost model for vaccine development that is a critical component of global efforts to prevent neglected and infectious diseases.Hookworm: The Sabin PDP is currently the only group developing a vaccine for human hookworm disease, an intestinal worm infection that infects more than 700 million people, causing anemia, malnutrition and abdominal pain. The Sabin PDP has two hookworm vaccine candidates currently in development. Our first candidate is undergoing Phase 1 clinical testing in Brazil and the United States; our second candidate is scheduled to soon enter Phase 1 clinical testing.Schistosomiasis: The Sabin PDP completed initial manufacture of our vaccine candidate and will soon enter Phase 1 clinical trials. Schistosomiasis is a parasitic disease spread by snails that infects more than 200 million people worldwide; left untreated, the disease can cause fever, organ failure, other chronic diseases and even death. Schistosomiasis is the most deadly parasitic disease after malaria, causing approximately 200,000 deaths annually. Chagas disease: Together with academic and industrial partners in Mexico, Germany, Japan and the United States, the Sabin PDP is developing a new therapeutic vaccine to target Chagas disease, a parasitic disease that can lead to heart failure and affects approximately 10 million people, primarily in Latin America. A therapeutic vaccine is currently in development that would offer a number of improvements over currently available treatments. Leishmaniasis: Since 2011, the Sabin PDP has been working to develop a vaccine to prevent cutaneous leishmaniasis, a parasitic infection transmitted by the bite of a sand fly that causes skin ulcers. The project currently is in the early pre-clinical stage.Severe acute respiratory syndrome (SARS): The Sabin PDP together with partners in the private sector, academia and the military is working to develop and manufacture a vaccine in order to prevent potential SARS outbreaks and improve biodefense preparedness. 5507825 2788243 Global Network for Neglected Tropical Diseases Program - The Global Network for Neglected Tropical Diseases (Global Network) is dedicated to raising the awareness, political will, and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) - a group of disabling, disfiguring, and deadly diseases affecting more than 1.4 billion people worldwide living on less than $1.25 a day. In collaboration with the World Health Organization (WHO), national health ministries, international organizations, pharmaceutical companies, donors and affected communities, the Global Network strives to control and eliminate these diseases of poverty by 2020. In order to accomplish this, The Global Network develops coordinated advocacy and resource mobilization activities and promotes NTD control through integrated mass drug administration (MDA) according to guidelines set by the WHO. We also advocate for NTD control programs that have been integrated into existing delivery systems, including immunization campaigns, Child Health Days, school health programs, and Vitamin A campaigns. We have helped to create regional funding mechanisms that support these NTD control and elimination programs and seek to leverage cross-sectoral investments in water and sanitation, and other development and poverty reduction projects for a comprehensive approach to disease control efforts. The Global Network's advocacy efforts include appealing for increased funding of NTD projects by the U.S. and UK governments, and building awareness of NTDs through media placements, speeches, and educational visits. 6965911 809333 Vaccine Advocacy and Education Programs - The Sabin Vaccine Institute's Vaccine Advocacy and Education program works together with leading health experts and organizations to promote awareness and increased utilization of both existing and new, underutilized vaccines. In 2012, we held various events, including a journalist information session and vaccinology course, to discuss relevant research and updates that informed public health agendas related to rotavirus, meningococcal, typhoid fever, pertussis, rubella and pneumococcal disease. The Sabin Vaccine Institute continued to be responsible for the communications and advocacy needs of the Dengue Vaccine Initiative, a global partnership to increase the priority given to dengue vaccines. The Sustainable Immunization Financing (SIF) program operates in twelve African, and six Asian, pilot countries on advocacy-driven initiatives for sustainable immunization financing. SIF invites key stakeholders, parliamentarians, and members of ministries of health and finance to develop innovative financing solutions that sustain vital public health programs. Outputs from such meetings have ranged from declarations and ideas for tax-devoted funding to conceiving financing mechanisms, all in support of this initiative. The Coalition against Typhoid (CaT) is a global forum of health and immunization experts working to expedite and sustain rational, evidence-based decisions at the global, regional, national and municipal levels regarding the use of typhoid vaccines to prevent childhood enteric fever. CaT also works to define barriers to the adoption of typhoid vaccines in communities that would benefit most and the key activities that are needed to overcome them. The Sabin Vaccine Institute serves as the CaT Secretariat and is supported by a grant from the Bill & Melinda Gates Foundation. The CaT objectives are accomplished through the activities of its membership. The Sabin Vaccine Institute is establishing the International Association of Immunization Managers (IAIM). This is a global association being formed for and by managers of national immunization programs from the public or private sector. The Association will target immunization managers at the national and sub-national levels. The International Association of Immunization Managers aims to: establish international and regional networks of immunization managers for exchanging experiences, challenges, and solutions and provide them with opportunities to develop their technical and leadership capacities. Sabin will host the Secretariat for IAIM at its offices in Washington, DC. 19399334 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 1 70 1 0 0 0 0 0 0 0 0 0 0 X 10 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Morton Hyman 20.00 X X 0 0 0 Mike Whitham 1.00 X X 0 0 0 Allan Goldstein 1.00 X 0 0 0 Baroness Helene Hayman 1.00 X 0 0 0 Axel Hoos 1.00 X 0 0 0 Kevin Reilly 1.00 X 0 0 0 Gary Rosenthal 1.00 X 0 0 0 Philip Russell 5.00 X 23950 0 0 Marc Shapiro 1.00 X 0 0 0 Peter Thoren 1.00 X 0 0 0 Brian Davis 40.00 X 202293 0 22488 Michael Marine 40.00 X 285390 0 12151 Peter Hotez 10.00 X 75000 0 0 Ciro de Quadros 40.00 X 343970 0 1397 Neeraj Mistry 40.00 X 227580 0 13620 Michael McQuestion 40.00 X 188820 0 22017 Christopher Nelson 40.00 X 186792 0 21760 Marva Loblack 40.00 X 140104 0 17017 Marcia de Souza Lima 40.00 X 133992 0 19444 1807891 0 129894 12 0 1 0 Center for Disease Control and Preventio Financial Management Office POBo Atlanta GA 30333 Pertussis surveillance 179387 Echoditto One Davis Square Suite 302 Somerville MA 02144 Web development and online consultation 168148 Fraunhofer USA Inc POBox 673308 Detroit MI 48267 Vaccine testing and process improvements 141655 Pan American Health Organization 525 23rd Street NW Washington DC 200372895 Conduct studies on vaccine effectiveness 140000 Creative Collaborations 50B Pember Road London England UK Advocacy Campaign Manager 133372 7 16536 277279 25020942 4569 25314757 30674 30674 15000 16536 15000 0 Exchange rate gain 900099 842 842 842 25346273 0 0 31516 4132082 4132082 3700886 3700886 966639 767175 161321 38143 3331067 2622752 572915 135400 95004 77408 14195 3401 358869 292402 53621 12846 286031 224430 48018 13583 11420 9827 1593 13791 31 13760 52974 52974 3434699 3386786 47913 567441 454761 112572 108 329949 266562 59023 4364 15890 7042 8830 18 521422 49219 472203 1114696 1077701 9857 27138 2260006 2228325 26929 4752 2295 1554 741 20460 20460 96116 25895 70221 Dues/Subscriptions 46886 32301 8168 6417 Recruitment 31802 27313 1959 2530 Seminar/Training 12985 10722 2058 205 30156 4160 9937 16059 21433566 19399334 1716294 317938 22158396 24567247 2432250 2413487 57331 35893 268383 178909 296236 223912 85095 72324 34075 34075 25035530 27301935 3956238 2503493 445113 260964 216509 207101 4617860 2971558 X 1982925 2138685 18434745 22191692 20417670 24330377 25035530 27301935 3912707 0 X X 0 1 X 1 0 X 25512242 17123901 21076480 21900847 25314757 110928227 25512242 17123901 21076480 21900847 25314757 110928227 80781413 30146814 241594 92623 25207 24717 30674 414815 111343042 246594 0.27080 0.25480 X The Organization has maintained a continuous and bona fide program for solicitation of funds from the general public, community, government units, and other charities. The public support percentage for 2012 and 2011 was approximately 27% and 25%, respectively, since some donations for use in the Organization's charitable programs from several contributors were larger than anticipated. As contained in the program descriptions in Part III of the Form 990, the Organization's program services directly benefit the general public on a continuing basis. While certain large Foundation grants may continue in the near term, this support is crucial to the Organization's exempt purpose of promoting and contributing to the control of infectious and neglected tropical diseases. The Organization expects to continue to solicit qualifying public support to assist in carrying out these program. Finally, the Organization's governing body represents the broad interest of the public, with no one individual or related group of individuals having undue control or influence over the Organization's funding or affairs. These Board members bring important skill sets and qualifications that help the Organization plan and achieve its strategic objectives. Accordingly, the "facts and circumstances" substantiate that the Organization continues to operate as a public charity. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 1 860 1 65 0 1 860 0 0 1785 0 Explanation of Lobbying Activities: Part II-B, Line 1: The Institute engaged in the following lobbying activities during the year: - Sent letters to members of congress advocating for funding of the U.S. Agency for International Development's (USAID's) NTD program. - Sent e-mails and made postings on website. - The Institute's staff provided testimony before congress advocating for funding of USAID's NTD program and NTD research and development funding. - Held one-on-one meetings between Sabin staff and representatives. 296236 223912 72324 72324 Obligation under capital lease 6836 Deferred rent 200265 207101 X 25425494 64221 64221 25361273 -15000 -15000 25346273 21512787 64221 64221 21448566 -15000 -15000 21433566 Description of Uncertain Tax Positions Under FIN 48: Part X, Line 2: The Organization has no significant uncertain tax positions during the year ended December 2012. Part XI, Line 4b - Other Adjustments: Direct benefits provided to donors -15,000. Part XII, Line 4b - Other Adjustments: Direct benefits provided to donors -15,000. 1 Europe (Including Iceland & Greenland) - 0 0 Grants to recipients located in region NTD Control, Vaccine Development, Vaccine Advocacy and Education 2624060 South America - Argentina, Bolivia, 0 0 Grants to recipients located in region Vaccine Development 782883 East Asia and the Pacific - 0 0 Grants to recipients located in region NTD Control, Vaccine Development 293943 0 0 0 0 0 0 3700886 0 3700886 South America - Argentina, Bolivia, Vaccine Development 782883 EFT East Asia and the Pacific - Vaccine Development 125714 EFT Europe (Including Iceland & Greenland) - NTD Control 14800 EFT East Asia and the Pacific - NTD Control 168229 EFT Europe (Including Iceland & Greenland) - Vaccine Advocacy and Education 376000 EFT Europe (Including Iceland & Greenland) - NTD control 2200000 EFT Europe (Including Iceland & Greenland) NTD control 31302 EFT 3 2 0 0 0 0 0 0 Procedure for Monitoring Grants Outside the U.S.: Schedule F, Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X X 1 The Social Investment Consultancy 338 City Road London UK Development strategy and outreach 0 24680 52689 -28009 24680 52689 -28009 DC MD NY Art Show 31536 16536 15000 15000 31536 16536 15000 15000 15000 0 1 Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 1849427 Vaccine Development Pan America Health Organization 525 23rd Street NW Washington DC 20037 433116 Vaccine Advocacy The George Washington University 2300 I Street NW Washington DC 20147 530196584 501(c)(3) 1330409 Vaccine Development The University of Kansas Center for Research 2385 Irving Hill Road Lawrence KS 66045 480680117 145000 Vaccine Development The END Fund 115 Bloomingdale Avenue Wayne PA 19087 273941186 250000 NTD Control The World Bank 1818 H Street NW Washington DC 20433 120000 NTD Control 1 5 Procedure for Monitoring Grants in the U.S.: Part I, Line 2: Schedule I, Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X 0 0 0 0 0 0 0 0 0 Brian Davis 194293 0 8000 0 0 0 8000 0 14488 0 224781 0 0 0 Michael Marine 250390 0 35000 0 0 0 10000 0 2151 0 297541 0 0 0 Ciro de Quadros 298970 0 45000 0 0 0 0 0 1397 0 345367 0 0 0 Neeraj Mistry 220680 0 6900 0 0 0 0 0 13620 0 241200 0 0 0 Michael McQuestion 188820 0 0 0 0 0 7600 0 14417 0 210837 0 0 0 Christopher Nelson 186792 0 0 0 0 0 7600 0 14160 0 208552 0 0 0 Marva Loblack 140104 0 0 0 0 0 5639 0 11378 0 157121 0 0 0 Marcia de Souza Lima 128992 0 5000 0 0 0 5359 0 14085 0 153436 0 0 0 Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant. It is first reviewed by the Chief Operating Officer and then presented to the Chief Executive Officer and Finance Committee for their review and approval. Finally, it is presented to the full Board of Trustees for their review and approval before filing. Form 990, Part VI, Section B, line 12c The Organization's Ethics & Compensation Committee is responsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with the Compensation and Ethics Committee. The Organization uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation consultant and its own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement (Sabin's website). Other Fees Form 990, Part IX, line 11g Vaccine development program contract expenses : Program service expenses 1,257,858. Management and general expenses 0. Fundraising expenses 0. Total expenses 1,257,858. Sub-recipient contracting: Program service expenses 746,153. Management and general expenses 0. Fundraising expenses 0. Total expenses 746,153. Transcription Service: Program service expenses 10,487. Management and general expenses 0. Fundraising expenses 0. Total expenses 10,487. Tech Support: Program service expenses 49,487. Management and general expenses 18,609. Fundraising expenses 0. Total expenses 68,096. Human Resources Consulting: Program service expenses 1,803. Management and general expenses 18,967. Fundraising expenses 0. Total expenses 20,770. Software Support: Program service expenses 0. Management and general expenses 1,189. Fundraising expenses 0. Total expenses 1,189. Design Consultant: Program service expenses 6,929. Management and general expenses 9,148. Fundraising expenses 0. Total expenses 16,077. Advocacy Campaign Manager: Program service expenses 133,372. Management and general expenses 0. Fundraising expenses 0. Total expenses 133,372. Strategic Consultant/Program Advocate: Program service expenses 153,276. Management and general expenses 0. Fundraising expenses 0. Total expenses 153,276. Quality Assurance Consultant: Program service expenses 18,310. Management and general expenses 0. Fundraising expenses 0. Total expenses 18,310. Program Specialists: Program service expenses 915,665. Management and general expenses 0. Fundraising expenses 0. Total expenses 915,665. Other: Program service expenses 93,446. Management and general expenses 0. Fundraising expenses 0. Total expenses 93,446. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.